A comprehensive metabolic modeling of thyroid pathway in relation to thyroid pathophysiology and therapeutics

OMICS A Journal of Integrative Biology

Volumn 17, Issue 11, 2013, Pages 584-593

  Gupta, Manish Kumar ^a   Singh, Dev Bukhsh ^a   Shukla, Rohit ^a   Misra, Krishna ^b  

^a CSJM UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; G PROTEIN COUPLED RECEPTOR; HLA B ANTIGEN; HLA DQB1 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; SOMATOMEDIN; STAT3 PROTEIN; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROTROPIN; TRANSCRIPTION FACTOR AP 1;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; COLD EXPOSURE; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; ENDOSOME; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENETIC TRANSCRIPTION; GOITER; HYPOTHALAMUS; HYPOTHYROIDISM; LYSOSOME; METABOLISM; METABOLITE; METASTASIS; MITOCHONDRION; MOLECULAR INTERACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; THYROID CARCINOMA; THYROID CELL; THYROID DISEASE; THYROID FUNCTION; THYROID GLAND; THYROID HORMONE RELEASE; THYROID HORMONE SYNTHESIS; THYROTROPIN BLOOD LEVEL;

CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DATABASES, PROTEIN; GENE EXPRESSION REGULATION; HUMANS; HYPOTHALAMUS; HYPOTHYROIDISM; NF-KAPPA B; PITUITARY GLAND; PROTEIN INTERACTION MAPPING; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THYROID GLAND; THYROTROPIN; THYROTROPIN-RELEASING HORMONE; TRANSCRIPTION FACTOR AP-1;

EID: 84887079813     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2013.0007     Document Type: Article

References (70)

1. Abel ED, Ahima RS, Boers ME, Elmquist JK, and Wondisford FE. (2001). Critical role for thyroid hormone receptor beta 2 in the regulation of paraventricular thyrotropin-releasing hormone neurons. J Clin Invest 107, 1017-1023. (Pubitemid 32323411)
2. Arnaud-Lopez L, Usala G, Ceresini G, et al. (2008). Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet 82, 1270-1280.
3. Assenov Y, Ram?rez F, Schelhorn SE, Lengauer T, and Albrecht M. (2008). Computing topological parameters of biological networks. Bioinformatics 24, 282-284.
4. Barabasi AL, and Oltvai ZN. (2004). Network biology: Understanding the cell's functional organization. Nat Rev Genet 5, 101-113. (Pubitemid 38160277)
5. Barabasi AL. (2009). Scale-free networks: A decade and beyond. Science 325, 412-413.
6. Boykin C, Zhang G, Chen YH, et al. (2011). CucurbitacinIIa: A novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/ STAT3 phosphorylation. Br J Cancer 104, 781-789.
7. Bresson D, Rebuffat SA, and Peraldi-Roux S. (2005). Localization of the immunodominant region on human thyroid peroxidase in autoimmune thyroid diseases: An update. J Autoimmune Dis 2, 2.
8. Butcher EC, Berg EL, and Kunkel EJ. (2004). Systems biology in drug discovery. Nat Biotechnol 22, 1253-1259. (Pubitemid 39336778)
9. Calzone L, Gelay A, Zinovyev A, Radvanyi F, and Barillot E. (2008). A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 4, 173.
10. Cameron AC, and Windmeijer FAG. (1997). An R-squared measure of goodness of fit for some common nonlinear regression models. J Econometrics 77, 329-342. (Pubitemid 127382175)
11. Chen D, Frezza M, Schmitt S, Kanwar J, and Dou QP. (2011). Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 11, 239-253.
12. Cho YY, Shon HS, and Yoon HD. (2005). Management of a pregnant patient with Graves' disease complicated by propylthiouracil induced agranulocytosis. Korean J Intern Med 20, 335-338.
13. Clauset A, Shalizi CR, and Newman MEJ. (2009). Power-law distributions in empirical data. SIAM Rev 51, 661-703.
14. Demir E, Cary MP, Paley S, et al. (2010). The BioPAX community standard for pathway data sharing. Nat Biotechnol 28, 935-942.
15. Fekete C, and Lechan RM. (2007). Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: Role of neuronal afferents and type 2 deiodinase. Front Neuroendocrinol 28, 97-114. (Pubitemid 47033939)
16. Funahashi A Tanimura N, Morohashi M, and Kitano H. (2003). CellDesigner: A process diagram editor for gene-regulatory and biochemical networks. Biosilico1, 159-162.
17. Garg A, and Aggarwal BB. (2002). Nuclear transcription factorkappa B as a target for cancer drug development. Leukemia 16, 1053-1068. (Pubitemid 34618844)
18. Gupta MK, and Misra K. (2013). Modeling and simulation analysis of propylthiouracil (PTU), an anti-thyroid drug on thyroid peroxidase (TPO), thyroid stimulating hormone receptor (TSHR) and sodium iodide symporter (NIS) based on systems biology approach. Netw Model Anal Health Inform Bioinforma DOI: 10.1007/s13721-013-0023-0.
19. Gupta MK, Singh DB, Rath SK, and Misra K. (2012). Metabolic modeling and simulation analysis of thyroid disorder pathway. J Comput Sci Syst Biol 5, 52-61.
20. Hayden MS, and Ghosh S. (2004). Signaling to NF-kappa B. Genes Dev 18, 2195-2224.
21. Hucka M, Finney A, Bornstein BJ, et al. (2004). Evolving a lingua franca and associated software infrastructure for computational systems biology: The Systems Biology Markup Language (SBML) project. Systems Biology 1, 41-53.
22. Hussain AR, Ahmed SO, Ahmed M, et al. (2012). Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 7, e39945.
23. Ideker T, and Krogan NJ. (2012). Differential network biology. Mol Syst Biol 8, 565.
24. KalloI, Mohacsik P, Vida B, et al. (2012). A novel pathway regulates thyroid hormone availability in rat and human hypothalamic neurosecretory neurons. PLoS One 7, e37860.
25. Kell DB. (2006). System biology, metabolic modeling and metabolomics in drug discovery and development. Drug Discov Today 11, 1085-1092. (Pubitemid 44810914)
26. Kenney JW, Poole RL, Adoff MD, Logue SF, and Gould TJ. (2012). Learning and nicotine interact to increase CREB phosphorylation at the jnk1 promoter in the hippocampus. PLoS One 7, e39939.
27. Ko hrle J. (2005). Selenium and the control of thyroid hormone metabolism. Thyroid 15, 841-853.
28. Lawrence T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1, a001651.
29. Le Novere N, Hucka M, Mi H, et al. (2009). The Systems biology graphical notation. Nat Biotechnol 27, 735-741.
30. Lin N, Urabe K, Moroi Y, et al. (2006). Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans. Eur J Dermatol 16, 262-265. (Pubitemid 43736146)
31. Liu Y, Li C, and Lin J. (2010). STAT3 as a therapeutic target for glioblastoma. Anticancer Agents Med Chem 10, 512-519.
32. Miranda P, Giraldez T, de la Pen a P, et al. (2005). Specificity of TRH receptor coupling to G-proteins for regulation of ERG K+ channels in GH3 rat anterior pituitary cells. J Physiol 566, 717-736. (Pubitemid 41122656)
33. Mondul AM, Weinstein SJ, Bosworth T, Remaley AT, Virtamo J, and Albanes D. (2012). Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One 7, e47730.
34. Monga V Meena CL, Kaur N, and Jain R. (2008). Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem15, 2718-2733.
35. Morshed SA, Latif R, and Davies TF. (2009). Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150, 519-529.
36. Mueller S, Kleinau G, Jaeschke H, Paschke R, and Krause G. (2008). Extended hormone binding site of the human thyroid stimulating hormone receptor: Distinctive acidic residues in the hinge region are involved in bovine thyroid stimulating hormone binding and receptor activation. J Biol Chem 283, 18048-18055.
37. Nakashima T, Taurog A, and Riesco G. (1978). Mechanism of action of thioureylene antithyroid drugs: Factors affecting intrathyroidal metabolism of propylthiouracil and methimazole in rats. Endocrinology 103, 2187-2197. (Pubitemid 9075959)
38. Nanjappa V, Raju R, Muthusamy B, et al. (2011). A comprehensive curated reaction map of leptin signaling pathway. J Proteomics Bioinform 4, 184-189.
39. Neumann S, Eliseeva E, McCoy JG, et al. (2011). A new smallmolecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96, 548-554.
40. Neumann S, Pope A, Geras-Raaka E, Raaka BM, Bahn RS, and Gershengorn MC. (2012). A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid 22, 839-843
41. Neumann S, Raaka BM, and Gershengorn MC. (2009). Human TSH receptor ligands as pharmacological probes with potential clinical application. Expert Rev Endocrinol Metab 4, 669.
42. Newman MEJ, Watts DJ, and Barabasi A. (2006). The Structure and Dynamics of Networks. Princeton University Press, Princeton.
43. Nillni EA, Vaslet C, Harris M, Hollenberg A, Bjørbak C, and Flier JS. (2000). Leptin regulates prothyrotropin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. J Biol Chem 275, 36124-36133.
44. Nillni EA. (2010). Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol 31, 134-156.
45. Perello M, Stuart RC, and Nillni EA. (2006). The role of intra cerebroventricular administration of leptin in the stimulation of prothyrotropin releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 147, 3296-3306. (Pubitemid 43901120)
46. Porcu E, Medici M, Pistis G, et al. (2013). A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet 9, e1003266.
47. Rawal R, Teumer A, Vo lzke H, et al. (2012). Meta-analysis of two genome-wide association studies identifies four genetic loci associated with thyroid function. Hum Mol Genet 21, 3275-3282.
48. Riesco-Eizaguirre G, and Santisteban P. (2006). A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155, 495-512. (Pubitemid 44608424)
49. Rivas M, and Santisteban P. (2003). TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 213, 31-45. (Pubitemid 38229153)
50. Ruf J, and Carayon P. (2006). Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys 445, 269-277. (Pubitemid 43082220)
51. Sato H, Minagawa M, Sasaki N, et al. (2011). Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: Efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab 24, 257-263.
52. Schapira M, Raaka BM, Das S, et al. (2003). Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci USA 100, 7354-7359. (Pubitemid 36706441)
53. Shannon P, Markiel A, Ozier O, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504. (Pubitemid 37428274)
54. Simm D, Pfarr N, Pohlenz J, Prawitt D, and Do rr HG. (2009). Two novel mutations in the human thyroid peroxidase (TPO) gene: Genetics and clinical findings in four children. Acta Paediatr 98, 1057-1061.
55. Sun Y, Lu X, and Gershengorn MC. (2003). Thyrotropinreleasing hormone receptors-Similarities and differences. J Mol Endocrinol 30, 87-97.
56. Swain M, Swain T, and Mohanty BK. (2005). Autoimmune thyroid disorders-An update. Indian J Clin Biochem 20, 9-17.
57. Szkudlinski MW, Fremont V, Ronin C, and Weintraub BD. (2002). Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82, 473-502. (Pubitemid 34654459)
58. Tajima T, Tsubaki J, and Fujieda K. (2005). Two novel mutations in the thyroid peroxidase gene with goitrous hypothyroidism. Endocr J 52, 643-645. (Pubitemid 41609057)
59. Tegeder I, Niederberger E, Israr E, et al. (2001). Inhibition of NFkappaB and AP-1 activation by R-and S-flurbiprofen. FASEB J 15, 595-597.
60. Toyoda N, Kaptein E, Berry MJ, Harney JW, Larsen PR, and Visser TJ. (1997). Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyroninedeiodinases. Endocrinology 138, 213-219. (Pubitemid 27009426)
61. Vallabhajosyula RR, Chakravarti D, Lutfeali S, Ray A, and Raval A. (2009). Identifying hubs in protein interaction networks. PLoS One 4, e5344.
62. Vanderpump MP. (2011). The epidemiology of thyroid disease. Br Med Bull 99, 39-51.
63. Weetman AP. (2003). Autoimmune thyroid disease: Propagation and progression. Eur J Endocrinol 148, 1-9. (Pubitemid 36175997)
64. Wonerow P, Neumann S, Gudermann T, and Paschke R. (2001). Thyrotropin receptor mutations as a tool to understand thyrotropin receptor action. J Mol Med (Berl) 79, 707-721. (Pubitemid 34025119)
65. Wu CC, Shete S, Chen WV, Peng B, Lee AT, Ma J, Gregersen PK, and Amos C.I. (2009). Detection of disease-associated deletions in case-control studies using SNP genotypes with application to rheumatoid arthritis. Hum Genet 126, 303-315.
66. Wu G, Zhu L, Dent JE, and Nardini C. (2010). A comprehensive molecular interaction map for rheumatoid arthritis. PLoS One 5, e10137.
67. Yen PM. (2001). Physiological and molecular basis of thyroid hormone action. Physiol Rev 81, 1097-1142. (Pubitemid 32606667)
68. Yu W, Wulf A, Liu T, Khoury MJ, and Gwinn M. (2008). Gene Prospector: An evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. BMC Bioinformatics 9, 528.
69. Zhan X, and Desiderio DM. (2010). Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics 3, 13.
70. Zinovyev A, Viara E, Calzone L, and Barillot E. (2008). BiNoM: A Cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics 24, 876-877. (Pubitemid 351386933)